ArticleRespiratory medicine case reports2025
Idiopathic pulmonary hemosiderosis: A pediatric case report.
Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Idiopathic pulmonary hemosiderosis (IPH) is a rare entity, which needs exclusion of all other possible etiologies. It mainly affects children and young adolescents, but still can come at any age. Despite its rarity, it has many consequences which can lead to significant morbidity if not diagnosed and managed. This report presents the first documented case of IPH in Palestine, highlighting the need for increased awareness and timely recognition of this condition in clinical practice, even in regions where it has not been previously reported. Case presentation: We report the case of a 14-year-old female diagnosed with IPH at the age of 5. She has a history of recurrent hemoptysis and two intensive care unit (ICU) admissions for diffuse alveolar hemorrhage and acute respiratory distress syndrome (ARDS). Investigations including a high-resolution computed tomography (HRCT) scan of the chest, revealed ground-glass opacities and nodularity. Bronchoalveolar lavage (BAL) and transbronchial biopsy (TBB) confirmed the diagnosis of IPH complicated by interstitial lung disease. Management included corticosteroid therapy at first; however, due to suboptimal response, a steroid-sparing immunosuppressive agent was added. Conclusion: This case is the first reported case of IPH in Palestine, it underscores the importance of recognizing rare diseases in underreported regions. IPH suspicion and diagnosis are challenging. Despite its rarity, it remains one of the causes of diffuse alveolar hemorrhage (DAH). This case highlightes the importance of early recognition and diagnosis of IPH, in order to start an appropriate management strategy and improve outcomes and emphasizes the need for further research into the epidemiology, optimal therapeutic approaches, and long-term outcomes of IPH in diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.